This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (108)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Use of Fenfluramine and Phentermine Alone and in Combination

Michael Weintraub, MD; Jeffrey D. Hasday, MD; Alvin I. Mushlin, MD; Dean H. Lockwood, MD

Arch Intern Med. 1984;144(6):1143-1148.

Abstract
• We performed a double-blind, controlled clinical trial comparing phentermine resin (30 mg in the morning), fenfluramine hydrochloride (20 mg three times a day), and a combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg before the evening meal), and placebo. We combined low doses of the two drugs to maintain efficacy while diminishing adverse effects. Eighty-one people with simple obesity (130% to 180% of ideal body weight) participated. Individualized diets were prescribed and discussed again during the 24-week study period. Weight loss in those receiving the combination (8.4±1.1 kg; mean±SEM) was significantly greater than in those receiving placebo (4.4±0.9 kg; Scheffé's test) and equivalent to that of those receiving fenfluramine (7.5±1.2 kg) or phentermine (10.0±1.2 kg) alone. Adverse effects were less frequent with the combination regimen than with other active treatments. Thirty-seven participants dropped out of the study, 18 for reasons related to drug treatment. Combining fenfluramine and phentermine capitalized on their pharmacodynamic differences, resulting in equivalent weight loss, fewer adverse effects, and better appetite control.

(Arch Intern Med 1984;144:1143-1148)

Author Affiliations
From the Departments of Preventive, Family, and Rehabilitation Medicine (Dr Weintraub), and Medicine (Drs Hasday, Mushlin, and Lockwood), University of Rochester (NY) School of Medicine and Dentistry.

Footnotes
Accepted for publication Nov 26, 1983.

Reprint requests to Department of Preventive Medicine, PO Box 644, University of Rochester Medical Center, Rochester, NY 14642 (Dr Weintraub).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Weight-Loss Pharmacotherapy: A Brief Review
Huizinga
Clin. Diabetes 2007;25:135-140.
ABSTRACT | FULL TEXT  

Operation for anorexigen-associated valvular heart disease
Caccitolo et al.
J. Thorac. Cardiovasc. Surg. 2001;122:656-664.
ABSTRACT | FULL TEXT  

Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
Glazer
Arch Intern Med 2001;161:1814-1824.
ABSTRACT | FULL TEXT  

Echocardiographic Examination of Women Previously Treated With Fenfluramine: Long-term Follow-up of a Randomized, Double-blind, Placebo-Controlled Trial
Davidoff et al.
Arch Intern Med 2001;161:1429-1436.
ABSTRACT | FULL TEXT  

Rapid Clot Formation and Abnormal Fibrin Structure in a Symptomatic Patient Taking Fenfluramine: A Case Report
Carr et al.
ANGIOLOGY 2001;52:361-366.
ABSTRACT  

Current and Potential Drugs for Treatment of Obesity
Bray and Greenway
Endocr. Rev. 1999;20:805-875.
ABSTRACT | FULL TEXT  

Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease
Prasad et al.
Ann. Thorac. Surg. 1999;68:1840-1841.
ABSTRACT | FULL TEXT  

Effects of Phentermine on Responding Maintained under Multiple Fixed-Ratio Schedules of Food and Cocaine Presentation in the Rhesus Monkey
Wojnicki et al.
J. Pharmacol. Exp. Ther. 1999;288:550-560.
ABSTRACT | FULL TEXT  

Aminorex to Fen/Phen : An Epidemic Foretold
Fishman
Circulation 1999;99:156-161.
FULL TEXT  

The Use of a Clinical Practice Guideline to Manage and Verify the Weight Loss Outcomes of Patients Treated With Fen-Phen in Primary Care Settings
Pitts et al.
Nutr Clin Pract 1998;13:241-250.
ABSTRACT  

Beneficial Effect of Diazoxide in Obese Hyperinsulinemic Adults
Alemzadeh et al.
J. Clin. Endocrinol. Metab. 1998;83:1911-1915.
ABSTRACT | FULL TEXT  

Valvular Heart Disease Associated with Fenfluramine-Phentermine
Connolly et al.
NEJM 1997;337:581-588.
ABSTRACT | FULL TEXT  

Long-term Pharmacotherapy in the Management of Obesity: National Task Force on the Prevention and Treatment of Obesity
JAMA 1996;276:1907-1915.
ABSTRACT  

An Overview of the Efficacy and Safety of Fenfluramine and Mazindol in the Treatment of Obesity
Stahl and Imperiale
Arch Fam Med 1993;2:1033-1038.
ABSTRACT